Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept High Capacity Process in Rheumatoid Arthritis
NCT02378506Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Primary completion
- May 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of etanercept in rheumatoid arthritis (RA), sponsored by Pfizer. Primary endpoint: Percentage of Participants With Positive Etanercept Anti-Drug Antibody (ADA) Status. Started Apr 2015; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02378506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378506.